Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects | Nature Communications
Progression-free survival and overall survival. (a) Median PFS or MST... | Download Scientific Diagram
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer
Ryan Huey, MD on Twitter: "In pancreatic cancer, adjuvant mFOLFIRINOX vs Gemcitabine: median PFS 21 vs 12 mos, median overall survival 54.4 vs 35 months. Pancreatic cancer patients living 20 months longer!! #
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
Median overall survival (OS) and progression-free survival (PFS) in a... | Download Scientific Diagram
Progression-free survival (PFS) and overall survival (OS) time. Median... | Download Scientific Diagram
a Overall survival (OS) with median and confidence interval (CI). b... | Download Scientific Diagram
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
Progression Free Survival Curve. Median PFS 4.5 months 95% CI 3.5–5.3.... | Download Scientific Diagram
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials | Journal for ImmunoTherapy of Cancer
JCM | Free Full-Text | A Clinical Efficacy of PRRT in Patients with Advanced, Nonresectable, Paraganglioma-Pheochromocytoma, Related to SDHx Gene Mutation
Progression-free Survival Data for Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib) Global HCP Website
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
Progression-Free Survival - WM | IMBRUVICA® (ibrutinib) HCP
Progression-free Survival Data for Metastatic Colorectal Carcinoma | STIVARGA® (regorafenib) Global HCP Website
a) Median progression-free survival (PFS) to second-line (SL) therapy.... | Download Scientific Diagram
Kaplan-Meier analysis of (a) progression-free survival (PFS); and (b)... | Download Scientific Diagram
Kaplan-Meier curves for progression-free survival (PFS; median 3.0... | Download Scientific Diagram
Median Overall Survival (mOS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Median progression-free survival (PFS), duration of response (DOR), and... | Download Scientific Diagram
Progression-free survival (PFS) curve and overall survival (OS) curve... | Download Scientific Diagram
Progression-free survival (median PFs, 206 days; 95% ci, 153-259) and... | Download Scientific Diagram
Progression-Free Survival (PFS) | ENHERTU® (fam-trastuzumab deruxtecan-nxki)
Kaplan–Meier plot of progression-free survival Median progression-free... | Download Scientific Diagram
Efficacy of TAGRISSO® (osimertinib) in Metastatic EGFRm NSCLC
